Health Vidya

These highlights do not include all the information needed to use EYDENZELT safely and effectively. See full prescribing information for EYDENZELT. EYDENZELT® (aflibercept-boav) injection, for intravitreal use Initial U.S. Approval: 2025 EYDENZELT® (aflibercept-boav) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of EYDENZELT has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to EYLEA® (aflibercept)